secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017859
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q1 net loss $45.9M, cash $669.3M; on track for latozinemab INFRONT-3 regulatory engagement in mid-2023
--------------------------------------------------------------------------------

- Revenue $16.5M (down $8M YoY); net loss $45.9M ($0.55/share) vs $44.6M ($0.54/share) in Q1 2022.
- Cash, equivalents and investments $669.3M; management expects runway through 2025.
- On track to discuss INFRONT-3 (latozinemab in FTD-GRN) with regulators mid-2023; data readout early 2025.
- Received $17.8M milestone from AbbVie for AL002 LTE enrollment; INVOKE-2 top-line data expected Q4 2024.
- 2023 guidance: collaboration revenue $15-25M, R&D expense $225-245M, G&A $60-70M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017023017859/0000950170-23-017859-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017023017859/alec-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017859

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer